Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up registry for Posoleucel clinical trial participants
ISRCTN31439492Phase 4Recruiting
- Sponsor
- ICON
- Start
- Jan 2022
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 4, open-label, single-arm trial of posoleucel in adenoviral infection, BK polyomavirus infection, progressive multifocal leukoencephalopathy (PML) and 3 more, sponsored by ICON. Primary endpoint: Incidence of adverse drug reactions related to Posoleucel. Started Jan 2022; status: recruiting.
02
Drugs
posoleucel
03
Conditions
adenoviral infectionBK polyomavirus infectionprogressive multifocal leukoencephalopathy (PML)human herpesvirus 6 infectionEpstein-Barr virus infection
Beyond the preview
Go deeper on ISRCTN31439492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN31439492.